Found 2 results
Filters: Author is M.B. Daldegan  [Clear All Filters]
G. S. Lordelo, Miranda-Vilela, A. L., Akimoto, A. K., Alves, P. C. Z., Hiragi, C. O., Nonino, A., Daldegan, M. B., Klautau-Guimarães, M. N., and Grisolia, C. K., Association between methylene tetrahydrofolate reductase and glutathione S-transferase M1 gene polymorphisms and chronic myeloid leukemia in a Brazilian population, vol. 11, pp. 1013-1026, 2012.
Alves-Silva J, da Silva SM, Guimaraes PE, Ferreira AC, et al. (2000). The ancestry of Brazilian mtDNA lineages. Am. J. Hum. Genet. 67: 444-461. PMid:10873790 Anisimov VN (2007). Biology of aging and cancer. Cancer Control 14: 23-31. Barbosa CG, Souza CL, Moura Neto JP, Arruda MGB, et al. (2008). Methylenetetrahydrofolate reductase polymorphisms in myeloid leukemia patients from Northeastern Brazil. Genet. Mol. Biol. 31: 29-32. Barreiro LB, Laval G, Quach H, Patin E, et al. (2008). Natural selection has driven population differentiation in modern humans. Nat. Genet. 40: 340-345. PMid:18246066 Bowen DT, Frew ME, Rollinson S, Roddam PL, et al. (2003). CYP1A1*2B (Val) allele is overrepresented in a subgroup of acute myeloid leukemia patients with poor-risk karyotype associated with NRAS mutation, but not associated with FLT3 internal tandem duplication. Blood 101: 2770-2774. PMid:12468438 Campregher PV, Lorand-Metze I, Grotto HZW and Sonati MF (2004). Haptoglobin phenotypes in Brazilian patients with leukemia. Braz. J. Pathol. Lab. Med. 40: 307-309. Carter K and Worwood M (2007). Haptoglobin: a review of the major allele frequencies worldwide and their association with diseases. Int. J. Lab. Hematol. 29: 92-110. PMid:17474882 Chen CL, Liu Q and Relling MV (1996). Simultaneous characterization of glutathione S-transferase M1 and T1 polymorphisms by polymerase chain reaction in American whites and blacks. Pharmacogenetics 6: 187-191. PMid:9156696 Chin YM, Bosco JJ and Koh CL (1992). Analysis of ras gene mutations in acute myeloid leukemia by the polymerase chain reaction and oligonucleotide probes. Singapore Med. J. 33: 48-50. PMid:1598607 Cotton SC, Sharp L, Little J and Brockton N (2000). Glutathione S-transferase polymorphisms and colorectal cancer: a HuGE review. Am. J. Epidemiol. 151: 7-32. PMid:10625170 Crump C, Chen C, Appelbaum FR, Kopecky KJ, et al. (2000). Glutathione S-transferase theta 1 gene deletion and risk of acute myeloid leukemia. Cancer Epidemiol. Biomarkers Prev. 9: 457-460. PMid:10815689 Duthie SJ, Narayanan S, Brand GM, Pirie L, et al. (2002). Impact of folate deficiency on DNA stability. J. Nutr. 132: 2444S-2449S. PMid:12163709 Franco RF, Morelli V, Lourenco D, Maffei FH, et al. (1999). A second mutation in the methylenetetrahydrofolate reductase gene and the risk of venous thrombotic disease. Br. J. Haematol. 105: 556-559. PMid:10233437 Franco RF, Simoes BP, Tone LG, Gabellini SM, et al. (2001). The methylenetetrahydrofolate reductase C677T gene polymorphism decreases the risk of childhood acute lymphocytic leukaemia. Br. J. Haematol. 115: 616-618. PMid:11736945 Frezza M, Tritapepe R, Pozzato G and Di Padova C (1988). Prevention of S-adenosylmethionine of estrogen-induced hepatobiliary toxicity in susceptible women. Am. J. Gastroenterol. 83: 1098-1102. PMid:3421220 Fryer AA, Zhao L, Alldersea J, Pearson WR, et al. (1993). Use of site-directed mutagenesis of allele-specific PCR primers to identify the GSTM1 A, GSTM1 B, GSTM1 A,B and GSTM1 null polymorphisms at the glutathione S-transferase, GSTM1 locus. Biochem. J. 295: 313-315. PMid:8216235    PMCid:1134855 Hengstler JG, Arand M, Herrero ME and Oesch F (1998). Polymorphisms of N-acetyltransferases, glutathione S-transferases, microsomal epoxide hydrolase and sulfotransferases: influence on cancer susceptibility. Recent Results Cancer Res. 154: 47-85. Hiragi CO, Miranda-Vilela AL, Rocha DMS, Oliveira SF, et al. (2011). Superoxide dismutase, catalase, glutathione Gene polymorphisms associated with CML in Brazil peroxidase and gluthatione S-transferases M1 and T1 gene polymorphisms in three Brazilian population groups. Genet. Mol. Biol. 34: 11-18. PMid:21637536    PMCid:3085354 Hishida A, Terakura S, Emi N, Yamamoto K, et al. (2005). GSTT1 and GSTM1 deletions, NQO1 C609T polymorphism and risk of chronic myelogenous leukemia in Japanese. Asian Pac. J. Cancer Prev. 6: 251-255. PMid:16235982 Hur M, Park JY, Cho HC, Lee KM, et al. (2006). Methylenetetrahydrofolate reductase A1298C genotypes are associated with the risks of acute lymphoblastic leukaemia and chronic myelogenous leukaemia in the Korean population. Clin. Lab. Haematol. 28: 154-159. PMid:16706930 Ismail SI, Ababneh NA and Awidi A (2009). Methylenetetrahydrofolate reductase (MTHFR) genotype association with the risk of chronic myelogenous leukemia. Jordan Med. J. 43: 8-14. Kim DH, Xu W, Ma C, Liu X, et al. (2009). Genetic variants in the candidate genes of the apoptosis pathway and susceptibility to chronic myeloid leukemia. Blood 113: 2517-2525. PMid:19141860 Kim I, Lee KH, Kim JH, Ra EK, et al. (2007). Polymorphisms of the methylenetetrahydrofolate reductase gene and clinical outcomes in HLA-matched sibling allogeneic hematopoietic stem cell transplantation. Ann. Hematol. 86: 41-48. PMid:17028897 Landi S (2000). Mammalian class theta GST and differential susceptibility to carcinogens: a review. Mutat. Res. 463: 247-283. Lourenço GJ, Ortega MM, Nascimento H, Teori MT, et al. (2005). Polymorphisms of glutathione S-transferase mu1 (GSTM1) and theta 1 (GSTT1) genes in chronic myeloid leukaemia. Eur. J. Haematol. 75: 530-531. PMid:16313269 Ma J, Stampfer MJ, Giovannucci E, Artigas C, et al. (1997). Methylenetetrahydrofolate reductase polymorphism, dietary interactions, and risk of colorectal cancer. Cancer Res. 57: 1098-1102. PMid:9067278 Maciel ME, Oliveira FK, Propst GB, Bicalho MG, et al. (2009). Population analysis of xenobiotic metabolizing genes in South Brazilian Euro and Afro-descendants. Genet. Mol. Biol. 32: 723-728. PMid:21637445    PMCid:3036891 Miranda-Vilela AL, Alves PC, Akimoto AK, Lordelo GS, et al. (2010). Gene polymorphisms against DNA damage induced by hydrogen peroxide in leukocytes of healthy humans through comet assay: a quasi-experimental study. Environ. Health 9: 21. PMid:20444272    PMCid:2881052 Mitchell RJ, Carzino R and Janardhana V (1988). Associations between the two serum proteins haptoglobin and transferrin and leukaemia. Hum. Hered. 38: 144-150. PMid:3397067 Mondal BC, Paria N, Majumdar S, Chandra S, et al. (2005). Glutathione S-transferase M1 and T1 null genotype frequency in chronic myeloid leukaemia. Eur. J. Cancer Prev. 14: 281-284. PMid:15901999 Moon HW, Kim TY, Oh BR, Min HC, et al. (2007). MTHFR 677CC/1298CC genotypes are highly associated with chronic myelogenous leukemia: a case-control study in Korea. Leuk. Res. 31: 1213-1217. PMid:17156840 Nei M (1977). F-statistics and analysis of gene diversity in subdivided populations. Ann. Hum. Genet. 41: 225-233. PMid:596830 Nevo S and Tatarsky I (1986). Serum haptoglobin types and leukemia. Hum. Genet. 73: 240-244. PMid:3460960 Nowicki MO, Falinski R, Koptyra M, Slupianek A, et al. (2004). BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks. Blood 104: 3746-3753. PMid:15304390 Oliveira JB, Bidere N, Niemela JE, Zheng L, et al. (2007). NRAS mutation causes a human autoimmune lymphoproliferative syndrome. Proc. Natl. Acad. Sci. U. S. A. 104: 8953-8958. PMid:17517660    PMCid:1885609 Ozkan Y, Yardim-Akaydin S, Firat H, Caliskan-Can E, et al. (2007). Usefulness of homocysteine as a cancer marker: total thiol compounds and folate levels in untreated lung cancer patients. Anticancer Res. 27: 1185-1189. PMid:17465261 Queiroz EP (2006). A Migração Intrametropolitana no Distrito Federal e Entorno: O Conseqüente Fluxo Pendular e o Uso dos Equipamentos Urbanos de Saúde e Educação. Available at []. Accessed May 6, 2011. Rebbeck TR (1997). Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiol. Biomarkers Prev. 6: 733-743. PMid:9298582 Robien K and Ulrich CM (2003). 5,10-Methylenetetrahydrofolate reductase polymorphisms and leukemia risk: a HuGE minireview. Am. J. Epidemiol. 157: 571-582. PMid:12672676 Robien K, Ulrich CM, Bigler J, Yasui Y, et al. (2004). Methylenetetrahydrofolate reductase genotype affects risk of relapse after hematopoietic cell transplantation for chronic myelogenous leukemia. Clin. Cancer Res. 10: 7592-7598. PMid:15569990 Rover Júnior L, Höehr NF, Vellasco AP and Kubota LT (2001). Sistema antioxidante envolvendo o ciclo metabólico da glutationa associado a métodos eletroanalíticos na avaliação do estresse oxidativo. Quim. Nova 24: 112-119. Sattler M, Verma S, Shrikhande G, Byrne CH, et al. (2000). The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells. J. Biol. Chem. 275: 24273-24278. PMid:10833515 Serre D and Hudson TJ (2006). Resources for genetic variation studies. Annu. Rev. Genomics Hum. Genet. 7: 443-457. PMid:16759172 Skibola CF, Smith MT, Kane E, Roman E, et al. (1999). Polymorphisms in the methylenetetrahydrofolate reductase gene are associated with susceptibility to acute leukemia in adults. Proc. Natl. Acad. Sci. U. S. A. 96: 12810-12815. Souza CL, Barbosa CG, Neto JPM, Barreto JH, et al. (2008). Polymorphisms in the glutathione S-transferase theta and mu genes and susceptibility to myeloid leukemia in Brazilian patients. Genet. Mol. Biol. 31: 39-41. Suarez-Kurtz G (2004). Pharmacogenomics in admixed populations: the Brazilian pharmacogenetics/pharmacogenomics network - REFARGEN. Pharmacogenomics J. 4: 347-348. PMid:15549130 Ulrich CM, Kampman E, Bigler J, Schwartz SM, et al. (1999). Colorectal adenomas and the C677T MTHFR polymorphism: evidence for gene-environment interaction? Cancer Epidemiol. Biomarkers Prev. 8: 659-668. PMid:10744125 van der Put NM, Gabreels F, Stevens EM, Smeitink JA, et al. (1998). A second common mutation in the methylenetet-rahydrofolate reductase gene: an additional risk factor for neural-tube defects? Am. J. Hum. Genet. 62: 1044-1051. PMid:9545395 Yano A, Yamamoto Y, Miyaishi S and Ishizu H (1998). Haptoglobin genotyping by allele-specific polymerase chain reaction amplification. Acta Med. Okayama 52: 173-181. PMid:9781267 Yi P, Pogribny I and Jill JS (2002). Multiplex PCR for simultaneous detection of 677 C→T and 1298 A→C polymorphisms in methylenetetrahydrofolate reductase gene for population studies of cancer risk. Cancer Lett. 181: 209.
C. A. P. Silveira, Daldegan, M. B., and Ferrari, I., Response to treatment with imatinib mesylate in previously treated chronic-phase chronic myeloid leukemia patients in a hospital in Brazil, vol. 10, pp. 2038-2048, 2011.
Baccarani M, Saglio G, Goldman J, Hochhaus A, et al. (2006). Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 108: 1809-1820. PMid:16709930 Baccarani M, Cortes J, Pane F, Niederwieser D, et al. (2009). Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J. Clin. Oncol. 27: 6041-6051. PMid:19884523 Bortolheiro TC and Chiattone CS (2008). Leucemia mielóide crônica: história natural e classificação. Rev. Bras. Hematol. Hemoter. 30: 3-6. Cervantes F, Hernandez-Boluda JC, Steegmann JL, Conde E, et al. (2003). Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon: results and prognostic factors for response and progression-free survival in 150 patients. Haematologica 88: 1117-1122. PMid:14555307 Cortes J and Kantarjian H (2003). Advanced-phase chronic myeloid leukemia. Semin. Hematol. 40: 79-86. Druker BJ, Tamura S, Buchdunger E and Ohno S (1996). Effects of a selective inhibitor of the ABL tyrosine kinase on the growth of BCR-ABL1-positive cells. Nat Med. 2: 561-566. PMid:8616716 Druker BJ, Talpaz MDM, Resta DJ, Peng B, et al. (2001). Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. New Engl. J. Med. 344: 1031-1037. PMid:11287972 Funke VAM, Medeiro CR, Lima DH, Setúbal DC, et al. (2005). Therapy of chronic myeloid leukemia with imatinib mesylate in Brazil: a study of 98 cases. Rev. Bras. Hematol. Hemoter. 27: 159-165. Giles FJ, Cortes JE, Kantarjian HM and O’Brien SM (2004). Accelerated and blastic phases of chronic myelogenous leukemia. Hematol. Oncol. Clin. North Am. 18: 753-74, xii. PMid:15271404 Goldman JM (2007). How I treat chronic myeloid leukemia in the imatinib era. Blood 110: 2828-2837. PMid:17626839 Goldman JM and Melo JV (2003). Chronic myeloid leukemia - advances in biology and new approaches to treatment. N. Engl. J. Med. 349: 1451-1464. PMid:14534339 Hochhaus A, Druker B, Sawyers C, Guilhot F, et al. (2008). Favorable long-term follow-up results over 66 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-α treatment. Blood 111: 1039-1043. PMid:17932248 Hughes TP, Kaeda J, Branford S, Rudzki Z, et al. (2003). Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N. Engl. J. Med. 349: 1423-1432. PMid:14534335 Kantarjian HM, Sawyers C, Hochhaus A, Guilhot F, et al. (2002a). Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N. Engl. J. Med. 346: 645-652. PMid:11870241 Kantarjian HM, Talpaz M, O’Brien S, Smith TL, et al. (2002b). Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results. Clin. Cancer Res. 8: 2177-2187. PMid:12114418 Kantarjian HM, Cortes JE, O’Brien S, Luthra R, et al. (2004a). Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha. Blood 104: 1979-1988. PMid:15198956 Kantarjian HM, O’Brien S, Cortes J and Giles F (2004b). Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous leukemia (CML-CP) after INF-α failure and in late CML-CP, comparison with historical controls. Clin. Cancer Res. 10: 68-75. PMid:14734453 Lahaye T, Riehm B, Berger U, Paschka P, et al. (2005). Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up. Cancer 103: 1659-1669. PMid:15747376 Lucas CM, Wang L, Austin GM, Knight K, et al. (2008). A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials. Leukemia 22: 1963-1966. PMid:18754023 O’Brien SG, Guilhot F, Larson RA, Gathmann I, et al. (2003). Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 348: 994-1004. PMid:12637609 Palandri F, Iacobucci I, Martinelli G, Amabile M, et al. (2008). Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML. J. Clin. Oncol. 26: 106-111. PMid:18165644 Quintás-Cardama A and Cortes J (2009). Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood 113: 1619-1630. PMid:18827185 Sawyers CL (1999). Chronic myeloid leukemia. N. Engl. J. Med. 340: 1330-1340. PMid:10219069 Silver RT, Woolf SH, Hehlmann R, Appelbaum FR, et al. (1999). An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood 94: 1517-1536. PMid:10477676 Sokal JE, Cox EB, Baccarani M, Tura S, et al. (1984). Prognostic discrimination in “good-risk” chronic granulocytic leukemia. Blood 63: 789-799. PMid:6584184 Thijsen S, Schuurhuis G, van Oostveen J and Ossenkoppele G (1999). Chronic myeloid leukemia from basics to bedside. Leukemia 13: 1646-1674. PMid:10557038 Vardiman JW, Melo JV, Baccarani M and Thiele J (2008). Chronic Myelogenous Leukaemia, BCR-ABL1 Positive. In: WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues (Swerdlow SH, Campo E, Harris NL, Jaffe ES, et al., eds.). IARC, Lyon, 32-37.